Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA-approved ophthalmic drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American Society of Cataract and Refractive Surgery – American Society of Ophthalmic Administrators Annual Meeting to be held in San Diego May 3-7, 2019. The presentation by Keith A. Walter, M.D., Professor of Ophthalmology at Wa